Syntaxin's Series C Round

Syntaxin raised a round of funding on November 12, 2010.

Syntaxin discovers and develops a new class of biopharmaceuticals, Targeted Secretion Inhibitors (TSIs) that treat disease through selective inhibition of cell secretory pathways. It is developing TSI…

Articles about Syntaxin's Series C Round: